BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI) announces today positive results of
a preliminary toxicity evaluation of test animals that formed part of its
xenograft model study, the results of which were announced September 5, 2012.
That study showed that BT211, biOasis conjugate of trastuzumab (Herceptin(R))
designed to treat brain metatastsis of HER2+ breast cancer halted the growth of
tumors in an animal xenograft model of human breast carcinoma.


The xenograft study was conducted by Biopharmaceutical Research, Inc., (BRI)
Vancouver, British Columbia, Canada and was designed to assess the antitumor
activity of BT2111. A secondary component of the study was a preliminary look at
potential tissue toxicity of BT2111. As such, the heart, kidneys and liver of
test animals were collected and submitted to Bellingham WA based Nova Pathology
for histopathological evaluation by light microscopy. The analysis was conducted
by Michael J. Tomlinson, D.V.M., Ph.D. The histopathology analysis looked at
organs from forty female mice that had been assigned to four treatment groups
(n=10 per group) as follows: PBS (saline) control; Herceptin(R); Transcend; and,
Transcend-Herceptin(R) conjugate (BT2111). The mice had been administered these
test compounds by intraperitoneal injections twice per week over a 40 day
period. The histologic findings were assigned semi-quantitative severity scores
based on the following scheme: Minimal = 1, Mild = 2, Moderate = 3, Marked = 4.
The histologic findings in animals dosed with Transcend, Herceptin(R) or
conjugated Transcend-Herceptin(R) conjugate (BT2111) were consistent with
findings in naive mice and were not different from the control group. The report
concluded that, "Under the conditions of this study, there were no test
article-related histopathology findings."


In addition to the benign histopathology findings, BRI reported that the body
weights of animals in Herceptin(R); Transcend; and, Transcend-Herceptin(R)
conjugate (BT2111) groups were not statistically different from control animals
during the course of the treatment phase. This observation further suggests that
BT2111 was well tolerated under the conditions of this study.


"This microscopic examination of tissue from animals that had been administered
BT2111 over a 40 day period was our first opportunity to look for any
preliminary evidence of drug-related tissue damage in selected organs," said Rob
Hutchison, Chairman and CEO. "We were extremely pleased to see that in this
animal study, BT2111 did not cause any apparent organ toxicity, which is
obviously a very important observation going forward. As we continue to advance
the BT2111 program, extensive and rigorous toxicity studies will need to be
conducted to clearly establish the safety of this compound. However, we are very
encouraged by the findings to date."


ABOUT BT2111 - BT2111 is a conjugate between biOasis' Transcend brain delivery
vector and trastuzumab (trade name of Herceptin(R)), a humanized monoclonal
antibody used clinically in the treatment of HER2+ breast cancer. It is reported
that up to 30% of HER2+ breast cancer patients develop brain metastasis for
which therapeutic options are limited. Because of its ability to cross the
blood-brain barrier, biOasis is researching the potential of BT2111 for
treatment of HER2+ metastatic breast cancer in the brain.


Herceptin(R) is a registered trademark of Roche/Genentech.

ABOUT BIOASIS

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the Company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca.


Forward-Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward -looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024